Ramelteon acts as an MT 1 and MT 2 melatonin receptor agonist, showing higher affinities for these receptors than does the natural ligand Ramelteon induces sleep initiation and maintenance, as ...

Takeda-backed Ascentage Pharma Group (AAPG) has filed to raise up to $100M through a U.S. initial public offering. The Chinese drug developer didn't specify terms in its SEC filing, but indicated ...